Brussels, 21/11/2006 (Agence Europe) - On 21 November, the European Commission cleared the proposed acquisition of Schwarz Pharma Aktiengesellschaft of Germany by UCB SA of Belgium.
UCB is a publicly traded Belgian company active in the pharmaceutical sector. It is active in the research, development and commercialisation of innovative pharmaceutical and biotechnology products in three therapeutic areas: the central nervous system (CNS), inflammation and immunology (including allergies) and...